Tag:
monoclonal antibody
Latest Headlines
Latest Headlines
Eisai's pivotal hopes for ovarian cancer drug dashed by PhIII flop
Back in 2007 when Japan's Eisai agreed to pay $325 million in cash for the U.S.-based Morphotek, the pharma company had high hopes for the biotech's pipeline-leading drug focused on ovarian cancer. But those hopes could not live up to a pivotal test as farletuzumab, also known as MORAb-003, failed to hit a statistically significant goalpost for progression-free survival.
Amgen, Lilly turn in upbeat data on rival psoriasis drugs
In the hunt to develop targeted drugs against plaque psoriasis, Amgen and Eli Lilly reported positive study results.
Abcam's $155M Epitomics buyout expands antibody business
Bidding to up its game in the antibody business, the U.K.'s Abcam has snapped up California-based Epitomics for $155 million.
Xoma axing 84 jobs to save dollars for lead drug
Xoma ( $XOMA ) has rung in 2012 with major cutbacks and organizational changes. The Berkeley, CA-based biotech company aims to axe 84 jobs or 34% of its work force by the end of the first quarter with
Abbott inks $470M pact for Biotest's Ph2 RA antibody program
In another sign of just how hot antibodies have become in the rheumatoid arthritis arena, Abbott is plunking down $85 million up front and promising up to $385 million more to partner with Germany's
Micromet drug shows promise against severe blood cancer
While there's a way to go in proving the mettle of the drug, Micromet's experimental antibody blinatumomab wiped out cancer cells in nine of 12 patients with relapsed acute lymphoblastic leukemia
Report: Monoclonal antibodies set to drive drug-delivery growth
Monoclonal antibodies are designed to seek out and destroy particular cancer cells, no matter where they're found in the body. According to the market research firm Kalorama Information, a new group
Blockbuster antibodies face a unique set of challenges
When Bristol-Myers Squibb's Yervoy recently won approval from the FDA , the analysts at Deloitte Recap chalked that up as the 25th such regulatory milestone for a monoclonal antibody credited to a
PPD, Taijitu form new joint venture
North Carolina-based PPD has established a joint venture with Taijitu Biologics to develop and commercialize a technology platform for the discovery of first- and best-in-class monoclonal antibody
Blockbuster antibodies now face quick onslaught of biosimilars
A lineup of blockbuster monoclonal antibodies produced by a group of the world's top biopharma companies are now squarely in the crosshairs of the world's top biosimilar developers. Last Friday the
